TW310324B - - Google Patents
Download PDFInfo
- Publication number
- TW310324B TW310324B TW084112189A TW84112189A TW310324B TW 310324 B TW310324 B TW 310324B TW 084112189 A TW084112189 A TW 084112189A TW 84112189 A TW84112189 A TW 84112189A TW 310324 B TW310324 B TW 310324B
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- patent application
- pure
- scope
- item
- Prior art date
Links
- -1 aminocrotonic acid ester Chemical class 0.000 claims abstract description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 238000011049 filling Methods 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 239000012442 inert solvent Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- PAWSVPVNIXFKOS-UHFFFAOYSA-N 2-aminobut-2-enoic acid zwitterion Chemical compound CC=C([NH3+])C([O-])=O PAWSVPVNIXFKOS-UHFFFAOYSA-N 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 4
- 229940124277 aminobutyric acid Drugs 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 150000001993 dienes Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- WASQWSOJHCZDFK-UHFFFAOYSA-N diketene Chemical compound C=C1CC(=O)O1 WASQWSOJHCZDFK-UHFFFAOYSA-N 0.000 claims 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical group [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- ZDAGHXPROITMNS-UHFFFAOYSA-N [Cu].[CH2]CC Chemical compound [Cu].[CH2]CC ZDAGHXPROITMNS-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 230000002079 cooperative effect Effects 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 150000003254 radicals Chemical group 0.000 claims 1
- 229910052704 radon Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 abstract description 13
- 125000001475 halogen functional group Chemical group 0.000 abstract description 3
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract description 2
- PAWSVPVNIXFKOS-IHWYPQMZSA-N (Z)-2-aminobutenoic acid Chemical compound C\C=C(/N)C(O)=O PAWSVPVNIXFKOS-IHWYPQMZSA-N 0.000 abstract 2
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 abstract 2
- GDMUWXHYYIOKHS-UHFFFAOYSA-N 2-benzylidene-3-oxobutanoic acid Chemical compound CC(=O)C(C(O)=O)=CC1=CC=CC=C1 GDMUWXHYYIOKHS-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 abstract 1
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000003869 acetamides Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- HIJDMCUGEMQNNA-UHFFFAOYSA-N 1,2-dihydro-1,10-phenanthroline Chemical compound C1=CC2=CC=CN=C2C2=C1C=CCN2 HIJDMCUGEMQNNA-UHFFFAOYSA-N 0.000 description 1
- NWHKKDLPTKZXQK-UHFFFAOYSA-N 1,2-dioxin-4-one Chemical compound O=C1COOC=C1 NWHKKDLPTKZXQK-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- XFRBXZCBOYNMJP-UHFFFAOYSA-N 2,2,6-trimethyl-1,3-dioxin-4-one Chemical compound CC1=CC(=O)OC(C)(C)O1 XFRBXZCBOYNMJP-UHFFFAOYSA-N 0.000 description 1
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
- AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 description 1
- FEPAYYYXSMWSLX-UHFFFAOYSA-N 2-ethyl-5-phenyl-3h-1,2-oxazole-3-sulfonic acid Chemical compound OS(=O)(=O)C1N(CC)OC(C=2C=CC=CC=2)=C1 FEPAYYYXSMWSLX-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 101100231508 Caenorhabditis elegans ceh-5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 125000006182 dimethyl benzyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FSQQTNAZHBEJLS-UPHRSURJSA-N maleamic acid Chemical compound NC(=O)\C=C/C(O)=O FSQQTNAZHBEJLS-UPHRSURJSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PBMIETCUUSQZCG-UHFFFAOYSA-N n'-cyclohexylmethanediimine Chemical compound N=C=NC1CCCCC1 PBMIETCUUSQZCG-UHFFFAOYSA-N 0.000 description 1
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
S10324
五、發明説明(…,随:, 本發明涉及純對映異構之苯基取代-3, 5 -二羧酸衍生物的新的選擇性製備方法。 出版物 Angew. Chem. 1〇3, 1991,1587-1605 中敘述了 對於1, 4-二氫oifc啶類作爲鈣拮抗劑或鈣激動劑時的藥理 作用,其絶對立體化學構型是非常重要的,還以列表方式 提供了迄今可利用的以純對映異構形式製備該化合物的方 法。所有這些方法都強調用對掌性池(chiral pool)助劑分 離非對映的酯,其選擇過程本質上就是在製備過程中以及 在引入分子中或從分子中消除過程中常常會遇到的實質困 難性嘗試錯誤法。具體地消除大量的助劑,從技術和化學 的觀點看來,常常是很複雜的工作,因而導致收率降低。 現在已令人騖奇地發現了一種用馬來醯亞胺作助劑的高 選擇性方法。 本發明涉及一種製備式(I )之纯對映異構之苯基取代的1 ,4~二氫吡啶-3,5-二羧酸衍生物及其鹽的高選擇性新方法 (請先閱讀背面之注意事項再填离本頁) 4 、-° 經濟部中央樣準局員工消費合作杜印製 其中 R2
CH, R和.S C〇,R3 (I) R1和R3相同或不同,表示直鍵或支鏈的至多含8個碳原 子的垸基,該垸基任選地帶有直鏈或支鏈的至多含6 3
310324 Λ 7 Β7 修ιΕ
經濟部中央標準局員工消費合作社印製
五、發明説明(2 ) ;—L 個碳原子的垸氧基或雞基取代基,或表示含3 — 7個碳 原子的環垸基, R 2表示 R4 | ——R5 其中 R4和R5相同或不同,表示_素5氰基,乙缺基,三 氟甲氧基,甲硫基,硝基,三氟甲基或至多含4 個破原子的直鍵或支鍵燒基’键姆基’缺基或燒 氧基,並且取代基之一任選地表示氫, 該方法特徵在於純對映異構之式(Π )亞苄基化合物或式(Π a )亞苄基化合物通過與式(ffl j或(HI a )化合物在惰性溶劑 中,需要時在鹼存在下進行反應而轉化爲純的非對映異構 之式(IV a )和(IV b )1,4-二氫毗啶類, f J R2 〇 =/ u CH3 。
*R. S 其中 R 1和R2具有上述定義, A 表示氫或直鏈或支鏈的至多含8個碳原子的烷基’或 表示被相同或不同的下述取代基任選地至多三取代的 本紙張尺度適用中國國家標準(CNS ) Λ.4規格(210X 297公f ) (請先閱讀背面之注意事項再填寫本頁) 、-a Λ 7 Β7
|ν Ψ "liToT 310324 五、發明説明(3) 苯基或辛基’所述取代基是經基、硝基、画素、氰基 、羧基、三氟甲基、三氟甲氧基、至多含6個碳原子 的直鏈或支键規氧基,或者表示被式-腿6 R7或 -S〇2 R8所示基團任選取代的苯基或辛基, 其中 R6和R7相同或不同,並表示氫、苯基或直鏈或支鏈 的至多含5個破原子_的坑基,R8表示直鍵或支 鏈的至多含4個碳原子的烷基或苯基, 在上述反應中,採用純對映異構之式(Η )亞苄基化合物 時,與式(ffl )胺基丁烯酸酯反應,而採用式U a )亞苄基 化合物時,則與相應的純對映異構之式(ffl a )胺基丁烯酸 S旨反應, 〇 NH, (請先閲讀背面之注意事項fr填寫本頁) --¾ .co〆 (m)或 NH, N-A (Ilia) -CO. o
R, S
M 其中 R1和A具有上述定義 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家樣準(CNS ) A4规格(2丨0> 297公鳌_)
(IVa) 其中 R 1 ’ R 2和A具有上述定義, 然後’在溫和條件下用弱鹼消除馬來醯亞胺基團,如果需 要’分離出游離酸,用常規方法將羧基官能囤酯化。 本發明的方法可以用下述反應示意式中的通式以實例 式予以説明: UVh f請先閱讀背面之注意事if再填寫本I j 4 方 訂 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家梂準(CNS ) A4規格.ί 2丨ΟΧ 310324 八 7 . B7 修 ¢- 个ν '中 Η Η 五、發明説明(5) ^ 851-7 [A] NH,
n-ch,gsh5 + 〇 o
CN a CHII C-C〇2-(CH2)2-〇CH3 CO-CH, 異丙醇△ H3CO-(CH2)3-〇3C. XN 'Cixo o (請先閱靖背面之注意事項再填寫本頁) 、卜r 、CH, I 3
H
MX N .CH
I
H 訂 1.1,8-重氮-雙環[5.4.0]-7-+—唉烯 (DBU) 2. 绽基二味唑— 3. 異丙醇 h3ccmc:h2>2-o2c 4-二甲基胺基毗啶(DMAP)
Cl CO^—CH(GH3)7 經濟部中央橾準局貝工消費合作社印製 7 本紙張尺度逋用中國國家標準(CNS > A4规格(210X297公釐) A7 B7 iifi- ,L· i、發明説明(6) ^'hff ί〇Λ..... 7a [B]
CN
〇 八 CH, Ο ,NCH2^6H5 NH? \/Ccv(ch2>^ o
X H3c 、N’、CH
CN o
XI 異丙醇 Λ _ h3c〇.(〇h2)2〇2cv
C〇2im
CeH5 0 (請先閲讀背面之注意事項再填寫本頁)
J 1.1,8-重氮-雙環[5.4_0卜7-+—碟烯 (DBU) 2.碇基二咪咬
I H
CN 3.異丙醇,4-二甲基 膝基啶(DMAP) H3CO-(CH3)2-〇?c, h3ct N* I Η 'Cl .COj-CH(CH3)j 、CH, -11. 經濟部中央標準局員工消費合作社印裝 本發明的方法令人驚奇地以完姜的方式、很高的對映體 纯度和很高的產率得到式(I )的對掌性化合物。 和上述先前技術不同,本發明方法提供了高對映選擇性 路線,用以使用通式(IV.)和(IVa)化合物中的馬來酸亞胺 基團作爲助劑來合成純對映異構之取代的4~苯基-1, 4-二氣 地交-3,5-二竣酸衍生物,上述基團在兩種純對映異構形式 中都存在。而且,馬來酸-亞胺可以由相應的(R)-或(S)_馬 來酸經過單一簡單化學反應製得。本發明方法還有—個明 類區别是,與現有技術不同,作爲助劑的馬來链亞胺可以 容易地引入到通式(m的亞苄基化合物中或弓丨入到通式 本紙張尺度適用中國國家棣準(C:NS ) A4规格(210 X 297公雜.> Λ 7
Λ 7 ^ LL
五、發明説明(7 (Ilia)的胺基丁烯酸醋中。沉且,馬來酸亞膝基函可以用 弱鹼、在非常溫和的條件下,以很完美的方式從所有化合 物中選擇性地消除掉。還有,通過簡單而系统地改變通^ (IV)和(IVa)中馬來链益胺的基國A,便可以以涉及的二氣 〇比咬爲目的以最佳方式解決所遇到的難題。由於馬來駿兑 胺的剛性環狀結構,相應的純的非對映異構之式(jy/jy这) 二氫时咬不僅可以以很高的收率進行結晶,而且可以通過 實質上不同的結晶性質區分出來。 本發明的這些優點,即最终也可能使本發明的通式(1 ) 化合物獲得很高的收率,在使用任何已知助劑時都没有得 到實現。 本發明方法另一個優點,特别是從成本角度考慮,是整 個反應過程很短’複雜情況很少,並且甚至各種中間體都 可以很好的收率和高的非對映異構或對映異構純度獲得。 本發明方法就原理而論適用於合成對映體純的二氣咪突 -3, 5-二羧酸衍生物。 適用於(H a)和(ffl a)化合物反應的溶劑通常是所有在反 應條件下不發生變化的惰性有機溶劑。其中較好的有醇類 ,如甲醇、乙酵、丙醇或異丙醇,或醚類、如乙醚、二噁 烷、四氫砝喃、乙二醇二甲醚或二乙二酵二甲鰱,乙肘, 或醢胺類,如六甲基碑醢胺或二甲基甲醢胺,或乙酸或醏 類,如乙酸乙酯,或由代烴類,如二氣甲垸、四氣化碳, 或烴類,如苯、二甲苯或甲苯Q同樣,也可使用上述溶劑 的混合物,較好的是異丙醇a 本紙張尺度適用中國國家梯準(CNS ) A私見格(2丨Ox 299公漦) {靖先閃讀背面之注意事項4填寫本耳j 4 -τ-_ 7δ 經濟部中央標準局員工消費合作社印製 五、 發明説明( Λ 7 Β'·? -φ:~~^~~η- 一-HL— 反應溫度可以在一個基本範面内變化。通常,該方法在 20ec-12〇t;之間進行,較好的是6〇tJ-9(TC之間。 該反應可以在大氣壓力下進行,但也可以在升壓或減壓 條件(如0.5-80巴)下進行。通常,該反應在大氣壓力下 進行。 式(I)和(BI )化合物反應時適用的溶劑是乙酸乙酯或異 丙醇。 某些通式(H a)所示化合物是已知的或可通過常规方法 製備的,例如,使相應的醛與乙醯乙酸2-烷氧基垸基醏反 應。 通式(ΠΙ )化合物本身是已知的。 純對映異構之式(H)的亞爷基化合物是新的或者可用下 述反應來製備,即在惰性溶劑中並在一種鹼和一重援酸存 在下使通式(V)的醛與純對映異構之式(VI)的乙醯乙酸酯 反應 R2-CHO (V) 其中R2定義同上, h3c 0 0
〇-
N-A 經濟部中央標準局員工消費合作社印製 ο (Vi)
R, S A具有上述定義《 第一步中適用的溶劑爲所有在該反應條件下不發生變化 本紙張尺度適用中國國家標準(CNS〉Λ4規格(210x2yr公釐) (請先閱讀背面之注意事項洱填"本頁)
五、發明説明(9) 的惰性有機溶劑。其中較好的是酵類,如甲醇乙醇、丙 醇或異丙醇,或醚類,如乙醚、二嘌垸、四氣咔喃、乙二 酵一甲醚或二乙二酵二曱醚,乙聆,或醯胺類,如六甲基 碎链胺或二甲基甲链膝’或乙酸或酯類,如乙酸乙酯,或 由代煙類,如二氣甲燒、四氣化碳,或烴類,如苯或甲苯 。同樣,也可以使用上逑溶劑的混合物。二氣甲垸較好。 在第-步中更適用的驗是環胺類,如料、Cl _c3 _三 和二縣胺,如二和三乙基胺或她咬或二甲膝基口比咬。派 啶較好。 通常,驗的用量是0.001莫耳至0 1〇莫耳 _ 0.08莫耳,以莫耳醛爲基礎計算。 况通. 比較適用的酸是 通常’按每莫耳賴,酸的用量是::。 優選0.05-0.08莫耳。 ϋ‘1〇莫斗 第一步中反應溫度可在-個基本匕 方法在2{TC-12(TC範圍内、優遲在如化。1^常β 該方法可以在大氣壓力下、知凰说w L下進打 0.5-5巴 >,優選在大氣壓办下运行。、壓條件下進行(如 通式(V)的醛是已知的或可用常規 對映體純的通式(VI)化合物是舭从法製備° ,,^ /η 啊的’可通過下述反應製 備,即通式(VB)的(S)_或(R)-馬籴絲 亞膝與雙烯綱或雙烯 酮/丙酮加合物(2,2,三甲基 | 1,3~二噁英-4-酮)在 惰性溶劑中反應, 11 本紙張尺度適用中國國家標準(CNS ) Λ4规格(21〇><2()7公餐 n m m· If n^i I I —1— —HA ^ «—^i nn tf^i m HI nn V j ........ ml HI nn i f 、-&Λ (請先閱讀.背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 310324 A:7 ϋ:Π 五、發明説明(i0 ) >]a ί0. Ο
HO
Ν-Α * R, S Ο (VII) 經濟部中央標準局員工消費合作社印製 其中, A具有上述的定義, 通常,合適的溶劑是烴類,如苯、甲笨或二甲苯。優選 曱苯。 該反應在901〇-140·〇溫度範園内進行,優選lOOtMlO °C。 該反應通常在大氣壓下進行。然而,也可以在高於大氣 壓或低於大氣壓(如0.5-5巴範圍内)進行。 某些通式(VD)的純對異構之醯亞胺是已知的〔例如參見 THL 1990, 4949; Am. Chen. Soc·, 2589, 1989〕或 者可通過使(S)-(-) -或(R) -(-)-馬來酸與相應的胺在上述 的一種寧劑(優選二甲苯)中、在loot;-180·α (優選130 eC-150eC )溫度範圍内反應來製備。 雙烯網和2, 2, 6 -三甲基~1, 3~二鳴英_4 -酮是已知物。 通式(ffl a)的純對映異構之胺基丁烯酸酯是新的並且例如 可以通過在製備通式(VI)的上述乙贐乙酸醋的過程中現場 加入胺或銨鹽來製備。 合適的溶劑是在製備通式(VI)化合物時提到的那些溶劑 -12 - (請先閱讀背面之注意事項再填寫本頁 J. -τ^· 、v-s 本紙張尺度適用中國國家標準(CNS ) Λ4规格(210X297.公釐 B7 7、發明説明(11) 1修 广一_ rSh. ........日 $ 充 85. 1认-? 。與銨鹽進行的反應在水分離器中於鼴流條件下在甲苯中 進行。 (請先閲讀背面之注意事項再填湾本頁) 該反應在5(rc-12(TC、優選50·α-80·〇溫度範園内進行。 該反應通常在0.卜0.5巴的低於大氣譽下進行。但是, 它也可以在大氣愿力或高於大氣壓力(例如在1-5巴)下 進行。 適合的鍵鹽通常是有機或無機酸的銨鹽,如,乙酸按或 甲酸銨。優選乙酸銨。 純對映異構之式(IV)化合物是新的且可以按前述方法製備 〇 --¾. 在上述一種惰性溶劑中,優選在乙酸乙醏、四氫敁喃或 遑二者的混合物中’從對映髏'純的通式(JY)的1,[二氫 口比啶中消除取代的毗洛烷-2, 5-二_-3-基基團。 合適的驗通常是驗金屬破酸盥,例如碳酸鈉或碳酸钟, 或有機驗’例如三烷基胺,例如三乙胺、Ν_乙基嗎琳、Ν_ 甲基哌啶或二異丙基乙胺或二甲基胺基眯啶,丨,8_二氮 雜雙環[5, 4, 0]十-碳-7-稀(_)%,5_二氛雜雙環 [4, 3, 0]壬-5-_N)m氮雜雙環[5, 4, 〇] ^ 碳-7-埽。 經濟部中央標準局員工消費合作社印製 對於i莫耳對映體純的式(IV)化合物,驗的用量爲15 莫耳,優選卜2莫耳。 該反應在G.c-5(rc,aA_w行㈣室溫。 該反應通常在大氣壓力下進行。綠而,也可以在高於大 13 A7 五、發明説明(12
氣壓或低於大氣壓(例如在〇 5_5巴)下^ 不經分離游__映㈣_,式⑽ R2 R〇,C,
.CO-D
R,S (vm) 經濟部中央標準局員工消費合作社印t 其中 Rl和R2具有上述定義, D表示一個活性基圏,如咪峻基, 活化反應在上迷一種溶劑中s在乙酸乙醏存在下進行在 最後一步,將產品與一種適當的醇(R3 _〇ϊί)在一種上述的 鹼(優選Ν,Ν-二甲基胺基咪啶)存在下、在所述醇的迴 流溫度下反應’得_對映異構的本發明式⑴化合物。 活化竣酸時優選使用的助恥劑。魏使用的縮合 劑是習知縮合劑,如碳化二亞胺類,如Ν,Ν,二乙基_ , Ν, Ν -—丙基-’ Ν, Ν -二異丙基-,Ν,二環己基碳化 二亞胺,Ν- ( 3-二甲胺基異丙基卜Ν’_乙基碳化二益胺里 酸鹽,或者莰基化合物,如竣基二咪唑,或2_噫唑铋 化合物,如2-乙基-5-苯基-1, 2-噁唑磺酸獵或2-第三 丁基-5-甲基-異嗞唑铖高氣酸遵,或醯胺基化合物,如2_ 乙氧基-卜乙氧基默基1,2-二氫碴啉,或丙鱗酸酑,或 ~ 14 * (請先閲讀背面之注意事項年填寫本頁)
本紙張尺度適用中國國家標準(CNS) Α4規格(:?】〇Χ297..ϋ B7 B7 Η卜 十 _ ......Β5. 10.
五、發明説明(U 氣曱酸異丁酯,或苯並三唑氧基-三(二甲胺基)膦錄六 氟麟酸鹽。優選Ν, Ν,-二環己基破化二亞胺和锭基二咪唑 〇 通常,助劑的用量爲(相對於1莫耳游離羧酸> Ρ3莫 耳,優選卜1,5莫耳。 該方法可以在大氣壓力下、增高或降低壓力下(如〇 5_ 5巴)進行,優選在大氣壓力下進行。 活化的、純對映異構的式(va)i, 4-二氫毗嚏類是已知的 或可按上述方法製備。 根據本發明方法製備的、優選的式(I )之純對映異構的 化合物爲下述化合物及其鹽: 其中
Ri和以相同或不同,且, 表示直鏈或支鍵的至多含8個碳原子的境基(.可被含 至多5個碳原子的直鏈或支鏈烷氧基或羥基任選取代 ),或表示環丙基,環戊基,環己基或環庚基, R2表示基困 R4 經濟部中央橾準局員工消費合作社印製
其中 R4和R 5相同或不同,各種情沉下表示氟、溴、氣、 氰基、乙缺基、三氟f氧基、甲基、硝基、肀瑞 基、三氟甲基或者直鏈或支鏈的至多含3個碳原 15 - 本紙張尺度適财ϋϋ家帛_丨eNS > 210.Χ29Τ 公嫠 310324
Λ 7 HI it 五、發明説明(w ) 子的燒氧基,如果需要,該取代基中的一個表示 氫。 ---------:丨- (請先閱讀背面之注意事項再填寫本頁) 根據本發明方法製備的、更優選的式(I )所示化合物爲 下述化合物及其鹽: 其中 R1和R 3相同或不同,且 表示直鏈或支鏈的至多含8個碳原子的烷基(可被甲 氧基或羥基任選取代),或表示環丙基,環戊基,環 己基或環庚基, R2表示基團 R4
經濟部中央樣準局員工消費合作杜印装 其中 丨 R4和R 5相同或不同,表示氟、氣、氰基、乙缺基、 |
I I
三氟甲氧基、甲基、甲硫基、硝基、三氟甲基或 I 至多含3個碳原子的直鏈或支鏈烷氧基,如果需 | , 要,該取代基中的一個表示氫。 I | 按照本發明方法製備的特刹優選的純對映異構化合物是 | |
(4R)-和(4S)-4- ( 2-氣-3-氰基-苯基)-1 , 4-二氬~2,6- J
二甲基-oit啶-3,5-二甲酸異丙基(2-甲氧基乙基)酯。 I 根據本發明方法可以製得純紂映異構之式(I )所示的鹵 [ 代苯基取代的1,4-二氫毗啶類,它是有用的大腦活性藥物 i ,製備方法具有很高的對映異構選擇性,產品收率很高。 |
I -16 - 丨 本紙張尺度適用中國國家標準(C,NS ) A4規格(21〇x 297公t ) A. / B. 7五、發明説明(15 ), 原料化合物 實施例I (式VI) (3S)-1-苄基-3- ( 3-氧代丁醯氣基)-砒咯垸~2,5〜二_ itL Ά1L n -------- 〇
〇 經濟部中央標準局員工消費合作社印製 將2, 2, 6-三甲基--1, 3-二噁英-4-酮(6.6克,43 8毫 莫耳,95%純)滴加到N-苄基(S)-馬來醯亞胺(9.〇克, 43.8毫莫耳)[THL 1990, 4949〕在二甲笨(]8毫升)中 的130eC的溶液中。從反應混合物中蒸除生成的丙酮。在 130·〇繼續攪拌2小時,將反應液冷至50·〇,眞空下除去 溶劑。殘留物經矽膠柱層析純化(淋洗劑:乙醚)。將產 品各級分濃縮,得到11.8克(93¾)標題化合物。 1 Η 腿(CDC1 3 ) : <5=2.28 (s, 3H); 2.77 (dd, J:18 Hz, 5 Hz, 1H); 3.19 (dd, .1 = 18 Hz, 8 Hz, 1H); 3.56 (s, 2H),4.68 (AB系統,2H); 5.49 (dd, J=8 Hz, 5Hz, 1H); 7.25-7.42 ppm (m, 5H);烯醇(en〇i) h ;弱單峰,11.68ppm ) 〇 實施例 (3S)-3- ( 3-胺基丁烯醢氧基 > -卜苄基_咪咯垸„2,5-二 綱 -17 - f請先閱讀f面之注意事項再填寫本耳} .丁. ,-0 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0><29:7公釐) 發明説明(ie ) ιύ.-
N-CH-
經濟部中央標準局貝工消費合作社印I 將N-苄基-(S)-馬來醯亞胺(1700克,8.28莫耳)在6 8 升甲苯中的懸浮液在105eC加熱,用大約20分鐘加入2 2 6-三甲基-1,3-二場英-4-酮(85%純,1447克,8.65莫耳 )’生成的丙醐和甲苯一起蒸除。在100-105¾繼續搜掉 2小時’進一步蒸除丙酮/甲苯。將1升甲苯加入反應溶 液’將物料冷至701C。加入乙酸銨(1207克,15 ·7莫耳) 後,將混合物在水分離器中於651〇和250-300毫巴下迴流 3小時。加入3.4升乙酸乙酯,將物料冷至室溫,用飽和 NaHC〇3水溶液洗滌,用Naz SO^j乾燥有機相,於35„4(rc 眞空蒸除溶劑。殘留物吸收在4.2升異丙醇中,於25__65,(3 眞空蒸除溶劑。殘留物再吸收在2,5升異丙醇中。將懸浮 液迴流,其間固體溶解。將混合物冷至5_7^後,加χ1 8 升水,遽出沉殿產物,並用異丙醇/水(1:1,3 4升)洗藤 ,產品在5(Γ〇眞空乾燥。 產率1990克(83¾)熔點:104-105t; 1 H NMR (CDC13 ): 5=1.94 (s, 3H); 2.71 (dd, J=l8 Hz, 5Hz, 1H); 3.12 (dd, J=18Hz, 8Hz, 1H); 4.57 (s, 1H); 4.71 (AB系統,2H); 4,74 (S,寬,1H): 5‘4〇 (dd,-J,8Hz, 5Hz, 1H); 7.20-7.44 (m,'5H);?7.88pp. -18 (請先閱讀背面之注意事項再填寫本頁)
J 訂 本紙張尺度適用中國國家樣準(CNf} ) 現格(21〇χ297公後 Λ7 …~ — 五、發明説明(17) ^10^7 (s,寬,1H) 〇 實施例ιπ(式m (3’S)-2-乙醢基-3- ( 2-氣-3~氰基苯基)-2-丙烯酸卜苄 基时卷炫-2 ,5-二綱-3-基錯
I V^c«
(請先閱讀背面之注意事項再填寫本f ) ) ο 實施例I化合物(12.6克,43.6毫莫耳)和2-氣-3-氰基 苯甲醛(7.2克,43.6毫莫耳)在二氣甲•垸(80毫升)中 的溶液用哌啶(246毫克,2.8毫莫耳)和冰乙酸(168毫 克,2.8毫莫耳)處理,該混合物在水分離器中迴流18小 時。將二氣甲垸溶液冷至室溫後,用水(40毫升)洗滌, 用Na 3 S0 4乾燥,眞空濃缩。殘留物用矽膠進行柱層析( 淋洗劑:乙醚)。將產品級分濃縮後,得到13.0克(68%) 標題化合物,爲E/Z異構體混合物。 經濟部中央標準局員工消費合作社印裂 1 H NMR (CDC1 3 ) : 6 =2.30, 2.51 (2s, 3H); 2.70-2.87 (m, 1H); 3.08-3.33 (m, 1H); 4.63-4.80 (m, 2H) ;5.51-5.69 (m, 1H); 7.27^7.92 (ι, 9H). 實施例IV(式IV) (4R, 3’S)-4- ( 2-氣-3-氰基苯基)-1,4-二氫-2,6-二 甲基啶-3,5-二甲酸(卜苄基-毗咯垸,5-二酮-3- -19 - 太紙張尺;?谪用史國國家標準(CNS > A4钱棒(?UVx 310324
------ . ---’丨III―一-— ---- "― I 五、發明説明(18 ) ^ " >'i » 基)-(2-甲氧基乙基)酯 一
rrCN
h3c〇^^〇A h3c 方法A : 將實施例I化合物(8(K 0克,Ο .244莫耳)和2-乙醯基_ 3- ( 2-氣-3-氰基苯基)-2-丙烯酸(2-甲氧基乙基)醋( 83.29克,0.243莫耳)用異丙醇(11〇〇毫升)處理,將混 合物迴流8.5小時。冷至室溫,已經沉澱的粗產品各用1〇〇 毫升異丙醇洗滌兩次,在4(Γ〇眞空乾燥。將粗產品懸浮於 乙酸乙酯(200毫升)中,將懸浮液迴流1小時。待混合 物冷至室溫後,濾出產品,用乙酸乙醏(40毫升)洗務, 在50eC眞空乾燥。 收率:57.8 克(41%) 非對映體過量 2 99.5%(HPLC,Chi race 10D-H) 經濟部中央標準局員工消費合作杜印製 熔點 239-240¾ 1 H NMR (ds DMSO) : <5=2.26 (s, 6H); 2.68 (dd, J= 18Hz, 5Hz, 1H); 3.09 (dd, J=18Hz, 8Hz, 1H); 3.16 (s, 3H); 3.37-3.50 (ra, 2H); 3.95-4.12 (ra, 2H) ;4.52,4.64 (AB訊號,jab=15Hz, 2H); 5.25 (s, 1H); -20 - 本紙張:尺度適用中國國家標準(CNS ) M規格( n〇y 2()r 公釐 B7
五、發明説明(W
5.53 (dd, J=8 Hz, 5 Hz, 1H); 7.22-7.77 (m, 8H), 方法B (經I和ID) 實施例ΙΠ化合物(3 0克’ 6.9毫莫耳)和3-胺基丁烯酸 2-甲氧基乙基酯(1·1克,6.91莫耳)用乙酸乙酯(38毫 升)處理,該混合物迴流5小時。濾出已經沉澱的產品, 用乙酸乙S旨(3毫升)洗藤’於401C眞空乾燥。 收率:1.3克(33%) 非對映體過量^99.5% (HPLC, Chiracel 0D-H)
實施例V (4R)-4-(2-氣-3-象基·'苯基)_1,4-二氫-2, 6-二甲基 〇比啶-3, 5-二甲酸(咪唑基)-(2-甲氣基乙基)酯
NIH 經濟部中央襟隼局員工消費合作社印裝 將實施例IV化合物(73.9克,0.128莫耳)懸浮於乙酸 乙酯(480毫升)和四氫〇夫喃(96毫升)中,該懸浮液用1, 8-二氮雜雙環[5,4, 0]十一碳-7-烯(DBU,29.0毫升, 0.192莫耳)處理並在室溫挽摔12小時。然後,加入in HC1 ( 300毫升),該遝合物劇烈攪拌15分鐘。分出乙酸乙 酷相,分别用IN HC1 ( 150毫升)和飽和NaCl永溶液洗滌 -21 - 本紙張尺度適用中國國家標準(CNS ) A4规格(_21()X 297公韙) A 7 B7
五、發明説明<.2〇 ), 1 次,用 Na 2 SO 酸乙酷(420毫升)中。加入Ν, Ν’-缓基二咪咬(25·〇克 ,0.154莫耳)後,該混合物在室溫攪拌12小時,在(卜5,c 攙拌30分鐘。濾出已經沉澱的產品,用乙酸乙酯(25毫升 )洗務並眞空乾燥。 收率:42·6克(76%)熔點:180eC 1 H NMR (CDC1 3 ) : 5-1.90 (s, 3H); 2.48 (s, 3H); 3.22 (s, 3H); 3.40-3.52 (m, 2H); 4.10 ft, 2H); 5.58 (s, 1H); 6.02 (s, 1H); 7.08 (d, 1H); 7.25- 7.58 (i, 4H); 7.91 (s, 1H). 式(I )的二氫oit啶類 實施例1 (4R)-4-(2-氣-3-氰基-苯基)-1,4-二氟-2,6-二甲基 σ比啶-3,5-二甲酸(異丙基)(2~甲氧基乙基)酯 乾燥。眞空除去溶劑,殘留物吸^在乙 ----------^-- f琦先閑讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印策 h3c〇\/\
、〇-ch(ch3)? 實施例^/化合物(73.2克,166毫莫耳)和1^[,1^;::^滕 基毗啶(0.93克,7.6毫莫耳)在異丙醇(53〇毫升)中应 -22
本紙張尺度適用中國國家標準(CNS ) A4規,格(2丨〇 X 29T,fH Λ Λ
Α7 _____一— _Β7 五、發明説明(21 ) ― 流20’』、時。該反應混合物慢慢冷至並在攪拌1 小時。/慮出結晶的粗產品’用冷異丙酵(35毫升〉.洗膝, 眞空乾燥,該粗產品用乙酸乙酯(150毫升)/環己炫( 450毫升)再結晶後,得到53.2克(74%)嫖題化合物。
熔點:138-140eC
[ex 】S 二 +13.9 (c=l,CHC1 3 ) ---------^ .-----LI1T------雄丨 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印裝 準 I標 一家 i國 國 ί中 一用-I適‘.I 尺 紙
Claims (1)
- ABCD 申請專利範圍 寻利申請案第84112189號 ROC Fatent Appln. No.84112189 修正之申請專利砝騙中文本-附件· AlludedCLaims in Chinese - Eid. v、(民國補牟Γ月皇)—_— ~— (Submitted on January 28» 1997) 1. 一種製備式(I )純對映異構之苯基-取代之1, 毗嚏-3,5-二羧酸衍生物及其鹽的方法 氫 R2 R^X,XO,R3 Η *R和S (請先間讀背Λ之注意寧項再填寫本頁) L 其中, R1和R3相同或不同’表示具有至多4個碳原子的直鍵或分 支狀烷基,該垸基可任選地經具有至多4個碳原子的 直鏈或分支狀烷氧基取代, ’ R2表示 R4 訂R5 經濟部中央襟準局貝工消費合作衽印製 其中 Μ和R5相同或不同,表示鹵素或氰基,並且取代基之 —任選地表示氫, 該方法特徵在於令純對映異構之式(II)亞苄基化合物或 武(11 a )亞苄基化合物與式(JD )或(ffi a )化合物在惰性 〉容劑中,若需要,在驗存在下進行反應而轉化爲純的非 對陕異構之式(IV a )和(IV b )1 ,4-二氫毗啶類, 24 國國家槺準(CNS ) A4規格 (210X297養釐) 3103^4 —_____________-—------------------------------- Λ" i-:I' > 卜- '丨 f.平n t! Λ& BS 甙充8ftU3 C8 s DU, 六、申請專利範圍 經濟部中央標準局員工消費合作社印製 R? ,CO〆 in) (na) 〇<、ch3 其中 : R1和R2具有上述定義, A 表示氫或直鏈或支鏈的至多含8個碳原子的烷基’或 表示被相同或不同的下述取代基任選地至多三取代 的苯基或芊基,所述取代基#是羥基、硝基、鹵素、 氰基、羧基、三氟甲基 '三氟甲氧基、至多含6個複 原子的直鏈或支鏈烷氡基,或者表示被式—腿叹7或 -S〇2R8所示基團任選取代的苯基或¥基, 其中 R6和R7相同或不同,並表示氧、苯基或直鏈或支鏈的 至多舍5個碳原子的烷:ί>^8表示直鏈或支鏈的 至多含4個碳原子的烷墓或苯基, 在上述反應中,採用純對映異構之式(11)亞苄基化合 物時,與式(1D)胺基丁烯酸醋反應,而採用式(1 3)亞 苄基化合物時’則與相應的純對映異構之式(a )胺基 丁烯酸酯反應, -25.- 本紙張尺度逋用中國國家橾準(CNS ) Λ4规格(2丨Ο X 297公釐} ' aΟ N-A (請先閱讀背而之注意事項再填寫本頁) 310324h% EE D8 六、申請專利範圍 NH, NH, Ο-Ά -COjR' (111)或 一 c〇. N-A (Ilia) O fi/s 其中R1和A具有上述定義, R2CO,Ο Ο N-A (IVa) (請先間讀背16之注意事項再填寫本頁 Ο R2CO^ Λ (fVb) 訂 ο 經濟部中央標準局爲工消費合作社印裝 其中Ri,R2和A具有上述定義,然後,在溫和條仵下用弱鹼消除馬來醯亞胺基國,如果 需要,分離出游離酸,用®用方法將羧基官能圏醋化。 2.具式(I )之亞苄基化合物 26 本紙張尺度逋用中國國家標準(CNIS ) M规格(2丨0X297公釐) 城! 申請專利範圍 其中 B8 Cg mN-A R. S (II) 經濟部中央標準局員工消費合作社印装 R2具有申請專利範園第1項中所述的定義, A 表示氫或直鏈或支鏈的多至含8個碳原子的烷基, 或表示被相同或不同的下迷取代基任選地至多三取 代的苯基或节基,所述取代基是缠基、确基、齒素 氛基、鼓基、三氟曱基、三氟甲氧基、至多含6個 破原子的直鏈或支鏈垸氡基\或者表示被式 -NR 6 R 7或-S〇 2 R 8所示基國任選取代的苯基或苄 基, 其中R 6和R?相同或不同,並表示氫、苯基或直鏈 或支鏈的至多含5個碳原子的垸基,R8表示直鏈 或支鏈的至多含4個破原子㊅垸基或苯基。 •一種製備如申請專利範圍第2赞_對映異構之式(H) 亞卞基化合物的方法,其特徵忒使式(v)醛與式(贝 )純對映異構之乙醯乙酸酯類在惰性溶劑中並在一種鹼 和一種羧酸存在下反應 R2 -CH0 (V) ---------^ r------訂------Α I (請先閱讀背而之注意事項再填寫本頁) 其中 R2具有申請專利範圍第1項中所述的定義 27 本紙張尺度適用中國國家樣準(CNS) A4規格(210X297公釐)申請專利範圍 A8 B8 CK D8 Ο 1 A 、〇- ο f N-A O (VI) R.S 其中 A具有申請專利範圍第2項中'所述的定義 4.式(111 a )之純對映異棒之胺基丁烯酸酯類’ 〇 (請先聞讀背而之注意事項存填寫本頁) X NH, -CON-A Ο (Ilia) 、-* R. S 其中 A具有申請專利範圍第2項中所述的定義。 ^秦、 5.—種製備如申請專利範圍第4項所述的式(ffl a ί 異構之胺基丁烯酸酯類的方法,其特徵在於令式(YU) 之(S)-或(R)-馬來醯亞胺 經濟部中央棟準局貝工消費合作社印裝 準 標 家 國 國 中 用 適 度 尺 張 -紙 本A ο R 8 C I釐 ”公 310324 L—.· 86· 1. 28 A8 B8 C卞 DK 六、申請專利範圍 式中A具有如申請專利範園第2項中所述之定義’ 與雙烯酮或雙烯鲖/丙酮加合物於惰性溶劑中’且於50 至120·Ο之溫度下,藉原處添加胺或銨鹽I反應混合物 之方式進行反應。 6.具式(iVa)和(IVb)之1,4-二氫ait啶類經濟部中央標準局員工消费合作社印裝 其中 R1和R2具有申請專利範圍第1項中所述的定義, A具有申請專利範園第2項中哲述的定義。 7·—種製備如申請專利範圍第6_今式〇va )和(IV b )非 對映異構之1,4-二氧毗啶類的方法,其特徵在於使式( K )或式(II a )的亞苄基化合物按照申請專利範圍第1 項的方法在惰性溶劑中,若.需要,在一種驗存在下, 與式(DI )或式(ffl a )的胺基丁烯酸酯類反應。 —29… ---------^ >------訂------吟.1 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度逋用中國國家裸準(CNS > A4規格 (210X297公釐) 如32 4 修止 耘年月蝻充 86. H A8 BS α DH 申請專利範圍 8.具式(VI)之純對映異構之乙醯乙酸酯類 〇 H,C ^ 0人。. 0 II N-A (VI) 〇 R. S 其中 A具有申請專利範國第2項中所述的定義。 9種製備如申請專利範圍第8項之式(VI)乙醯乙酸酯類的 方法,其特徵在於令式(Vfl)之(S)-或(R)-馬來醢亞胺類 〇 Η(ΤM-A (VII) 0 * R, S 式中A具有如申請專利範圍第2項中所述.¾楚義, ,少"'、 在惰性溶劑中與雙烯酮或雙烯酮/丙銅'知合物2, 2, 6-三甲基-1,3 -二屬英-4-酮反應〇 _:.—--------—《^-------訂-------城 I (請先間讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 30 本紙張尺度適用中國國家標準(€呢)戍4规格(210父297_公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4443168A DE4443168A1 (de) | 1994-12-05 | 1994-12-05 | Neues hochselektives Verfahren zur Herstellung von enantiomerenreinen phenylsubstituierten 1,4-Dihydropyridin-3,5-dicarbonsäurederivaten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW310324B true TW310324B (zh) | 1997-07-11 |
Family
ID=6534908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW084112189A TW310324B (zh) | 1994-12-05 | 1995-11-17 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US5700948A (zh) |
| EP (2) | EP0716081B1 (zh) |
| JP (1) | JP3891500B2 (zh) |
| KR (1) | KR100396011B1 (zh) |
| CN (5) | CN1079793C (zh) |
| AT (1) | ATE322482T1 (zh) |
| AU (1) | AU702274B2 (zh) |
| CA (1) | CA2164276C (zh) |
| CZ (1) | CZ296438B6 (zh) |
| DE (2) | DE4443168A1 (zh) |
| DK (1) | DK0716081T3 (zh) |
| ES (1) | ES2262138T3 (zh) |
| FI (1) | FI115908B (zh) |
| HU (1) | HU214683B (zh) |
| IL (1) | IL116225A (zh) |
| MX (1) | MX9504954A (zh) |
| MY (1) | MY112938A (zh) |
| NO (1) | NO312832B1 (zh) |
| NZ (1) | NZ280578A (zh) |
| PL (1) | PL183604B1 (zh) |
| PT (1) | PT716081E (zh) |
| RU (1) | RU2155752C2 (zh) |
| SG (1) | SG73352A1 (zh) |
| SI (1) | SI0716081T1 (zh) |
| SK (1) | SK282428B6 (zh) |
| TW (1) | TW310324B (zh) |
| ZA (1) | ZA9510263B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110962A1 (en) * | 1999-12-10 | 2001-06-27 | Pfizer Inc. | Process for preparing 1,4-dihydropyridine compounds |
| KR102533154B1 (ko) | 2022-09-22 | 2023-05-17 | 임태형 | 안전계단 난간대 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932646A (en) * | 1971-04-10 | 1976-01-13 | Farbenfabriken Bayer Ag | Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate |
| DE2815578C2 (de) * | 1978-04-11 | 1986-01-16 | Bayer Ag, 5090 Leverkusen | Neue pharmazeutische Verwendung von Nimodipin |
| JPS6058239B2 (ja) * | 1978-07-20 | 1985-12-19 | 山之内製薬株式会社 | 新規セフアロスポリン誘導体 |
| DE2911029C2 (de) * | 1979-03-21 | 1985-03-14 | Kombi-Lift Montage- Und Handelsgesellschaft Mbh, 5650 Solingen | Vorrichtung zum Haltern der Führungsrollen für die Lastseile eines Fassadenseilaufzuges in einem oben am Gebäude fest angeordneten Gehäuse |
| GR850872B (zh) * | 1984-04-16 | 1985-11-25 | Yamanouchi Pharma Co Ltd | |
| US4539302A (en) * | 1984-04-30 | 1985-09-03 | E. I. Du Pont De Nemours And Company | Recovery of zerovalent nickel complexes |
| DE3423105A1 (de) * | 1984-06-22 | 1986-01-02 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung optisch aktiver 1,4-dihydropyridine |
-
1994
- 1994-12-05 DE DE4443168A patent/DE4443168A1/de not_active Withdrawn
-
1995
- 1995-11-16 MY MYPI95003487A patent/MY112938A/en unknown
- 1995-11-17 TW TW084112189A patent/TW310324B/zh active
- 1995-11-22 PT PT95118359T patent/PT716081E/pt unknown
- 1995-11-22 SI SI9530725T patent/SI0716081T1/sl unknown
- 1995-11-22 AT AT95118359T patent/ATE322482T1/de active
- 1995-11-22 DK DK95118359T patent/DK0716081T3/da active
- 1995-11-22 EP EP95118359A patent/EP0716081B1/de not_active Expired - Lifetime
- 1995-11-22 ES ES95118359T patent/ES2262138T3/es not_active Expired - Lifetime
- 1995-11-22 DE DE59511043T patent/DE59511043D1/de not_active Expired - Lifetime
- 1995-11-22 EP EP04009787A patent/EP1443043A3/de not_active Withdrawn
- 1995-11-28 MX MX9504954A patent/MX9504954A/es unknown
- 1995-11-28 US US08/563,725 patent/US5700948A/en not_active Ceased
- 1995-11-29 AU AU39150/95A patent/AU702274B2/en not_active Ceased
- 1995-11-30 PL PL95311539A patent/PL183604B1/pl not_active IP Right Cessation
- 1995-12-01 NZ NZ280578A patent/NZ280578A/en not_active IP Right Cessation
- 1995-12-01 JP JP33570795A patent/JP3891500B2/ja not_active Expired - Fee Related
- 1995-12-01 NO NO19954885A patent/NO312832B1/no not_active IP Right Cessation
- 1995-12-01 CA CA002164276A patent/CA2164276C/en not_active Expired - Fee Related
- 1995-12-01 IL IL11622595A patent/IL116225A/xx not_active IP Right Cessation
- 1995-12-01 HU HU9503438A patent/HU214683B/hu not_active IP Right Cessation
- 1995-12-04 FI FI955825A patent/FI115908B/fi not_active IP Right Cessation
- 1995-12-04 SG SG1995002018A patent/SG73352A1/en unknown
- 1995-12-04 ZA ZA9510263A patent/ZA9510263B/xx unknown
- 1995-12-04 KR KR1019950046341A patent/KR100396011B1/ko not_active Expired - Fee Related
- 1995-12-04 CZ CZ0320595A patent/CZ296438B6/cs not_active IP Right Cessation
- 1995-12-04 SK SK1526-95A patent/SK282428B6/sk not_active IP Right Cessation
- 1995-12-05 RU RU95121073/04A patent/RU2155752C2/ru not_active IP Right Cessation
- 1995-12-05 CN CN95119057A patent/CN1079793C/zh not_active Expired - Fee Related
-
1997
- 1997-07-16 US US08/896,275 patent/US5849924A/en not_active Expired - Lifetime
-
1998
- 1998-09-21 US US09/158,428 patent/US5910593A/en not_active Expired - Lifetime
-
1999
- 1999-03-25 US US09/276,220 patent/USRE36607E/en not_active Expired - Lifetime
- 1999-12-30 CN CN991275276A patent/CN1216054C/zh not_active Expired - Fee Related
- 1999-12-30 CN CN99127529A patent/CN1105102C/zh not_active Expired - Fee Related
- 1999-12-30 CN CN99127530A patent/CN1094926C/zh not_active Expired - Fee Related
- 1999-12-30 CN CN99127528A patent/CN1094486C/zh not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6011028B2 (ja) | 新規4−(ポリアルコキシ−フエニル)−2−ピロリドンの製法 | |
| FR2861071A1 (fr) | Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique | |
| TW310324B (zh) | ||
| JP5585822B2 (ja) | 光学活性ニペコチン酸誘導体の製造方法 | |
| JP3100444B2 (ja) | 1,4−ジヒドロピリジン誘導体及びその製造方法 | |
| CA1273931A (en) | Process for production of the dextrorotatory optical isomer of diastereomer a of ym-09730 | |
| JP2001081089A (ja) | 3−置換−4−フェニル−ピペリジン誘導体の製造方法 | |
| JP3091844B2 (ja) | 複素環式化合物 | |
| ITMI990364A1 (it) | Processo per la produzione di paroxetina | |
| JPH11506124A (ja) | 置換された3―アリール―3―カルボキシアルキルグルタルイミド、4―アリロ―4―シアノヘプタンジカルボン酸の環化によるこれらの製造方法、及び3―アリール―3―ヒドロキシアルキルピペリジンを製造するためのこれらの使用 | |
| US4495355A (en) | Optically-active diamide derivatives | |
| US20010053862A1 (en) | Process for preparing arylpiperidine carbinol intermediates and derivatives | |
| JPS63208573A (ja) | 光学活性な1,4−ジヒドロピリジン誘導体の製造方法 | |
| EP1140841B1 (fr) | Derives de 3-phenyl-2, 6-dioxopiperidin-3-yl propionamide et leur procede de preparation | |
| KR100354806B1 (ko) | 암로디핀 베실레이트의 신규 중간체 및 그의 제조방법 | |
| Kise et al. | Diastereoselective intermolecular coupling of chiral α-imino amides with ketones by electroreduction | |
| JPH0768241B2 (ja) | 光学活性な1,4―ジヒドロピリジン誘導体 | |
| JPH02212474A (ja) | 光学活性な1,4―ジヒドロピリジン誘導体の製造方法 | |
| JPH05230023A (ja) | 1,4−ジヒドロピリジン誘導体、その製法と用途 | |
| KR20030059724A (ko) | 이미다졸 유도체의 제조방법 | |
| JP2001261676A (ja) | アミノピリジン類二量体の製造方法 | |
| JPH02223554A (ja) | 複素環式誘導体の製造方法 | |
| KR20020049492A (ko) | 피리돈 유도체의 제조방법 | |
| JPH03209373A (ja) | ジベンゾジオキサゼシン及びジベンゾジオキサアザシクロウンデシン誘導体とこれらの化合物の製造方法並びにこれらの化合物を含有する医薬組成物 | |
| KR20010092941A (ko) | 바이시클로[3.3.1]노난 구조 화합물의 제조방법 |